Merging the Binding Sites of Aldose and Aldehyde Reductase for Detection of Inhibitor Selectivity-determining Features

Journal of Molecular Biology

Volumn 379, Issue 5, 2008, Pages 991-1016

  Steuber, Holger ^a   Heine, Andreas ^a   Podjarny, Alberto ^b   Klebe, Gerhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

aldose reductase; drug design; inhibitor; protein ligand interaction; selectivity determining features

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE 1; ALDOSE REDUCTASE 2; ALDOSE REDUCTASE INHIBITOR; FIDARESTAT; IDD 388; IDD 393; SORBINIL; TOLRESTAT; ZOPOLRESTAT;

ARTICLE; BINDING SITE; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; POINT MUTATION; PRIORITY JOURNAL; THERMODYNAMICS; X RAY ANALYSIS;

EID: 44349168793     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.03.063     Document Type: Article

References (49)

1. Rauh D., Klebe G., and Stubbs M.T. Understanding protein-ligand interactions: the price of protein flexibility. J. Mol. Biol. 335 (2004) 1325-1341
2. Teague S.T. Implications of protein flexibility for drug discovery. Nature Rev. Drug Discov. 2 (2003) 527-541
3. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegemann R.A., Pak J.Y., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384 (1996) 644-648
4. Bishop A.C., Buzko O., and Shokat K.M. Magic bullets for protein kinases. Trends Cell Biol. 11 (2001) 167-172
5. Davydov V.V., Dobaeva N.M., and Bozhkov A.I. Possible role of alteration of aldehyde's scavenger enzymes during aging. Expt. Gerontol. 39 (2004) 11-16
6. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 50 (1998) 21-33
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
8. Greene D.A., Arezzo J.C., and Brown M.B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53 (1999) 580-591
9. Suzen S., and Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem. 10 (2003) 1329-1352
10. Constantino L., Rastelli G., Vianello P., Cignarella G., and Barlocco D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med. Res. Rev. 19 (1999) 3-23
11. Yagihashi S., Yamagishi S.I., Wada Ri R., Baba M., Hohman T.C., Yabe-Nishimura C., and Kokai Y. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124 (2001) 2448-2458
12. Mylari B.L., Armento S.J., Beebe D.A., Conn E.L., Coutcher J.B., Dina M.S., et al. A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3-one. J. Med. Chem. 46 (2003) 2283-2286
13. Bohren K.M., Grimshaw C.E., and Gabbay K.H. Catalytic effectiveness of human aldose reductase. J. Biol. Chem. 267 (1992) 20965-20970
14. Sato S., and Kador P.F. Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochem. Pharmacol. 40 (1990) 303-307
15. Barski O.A., Gabbay K.H., Grimshaw C.E., and Bohren K.M. Mechanism of human aldehyde reductase: characterization of the active site pocket. Biochemistry 34 (1995) 11264-11275
16. Barski O.A., Gabbay K.H., and Bohren K.M. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry 35 (1996) 14276-14280
17. Jay D., Hitomi H., and Griendling K.K. Oxidative stress and diabetic complications. Free Radic. Biol. Med. 40 (2006) 183-192
18. Chang T., Wang R., and Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic. Biol. Med. 38 (2005) 286-293
19. Oya T., Hattori N., Mizuno Y., Miyata S., Maeda S., Osawa T., and Uchida K. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274 (1999) 18492-18502
20. El-Kabbani O., Ruiz F., Darmanin C., and Chung R.P.-T. Aldose reductase structures: implications for mechanism and inhibition. Cell. Mol. Life Sci. 61 (2004) 750-762
21. Darmanin C., Chevreux G., Potier N., VanDorsselaer A., Hazemann I., Podjarny A., and El-Kabbani O. Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry. Bioorg. Med. Chem. 12 (2004) 3797-3806
22. El-Kabbani O., Old S.E., Ginell S.L., and Carper D.A. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. Mol. Vis. 5 (1999) 20-25
23. El-Kabbani O., Wilson D.K., Petrash J.M., and Quiocho F.A. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol. Vis. 4 (1998) 19-25
24. Urzhumtsev A., Tete-Favier F., Mitschler A., Barbanton J., Barth P., Urzhumtseva L., et al. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 5 (1997) 601-605
25. Podjarny A., Cachau R.E., Schneider T., Van Zandt M., and Joachimiak A. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding. Cell Mol. Life Sci. 61 (2004) 763-773
26. El-Kabbani O., Carper D.A., McGowan M.H., Devedjiev Y., Rees-Milton K.J., and Flynn T.G. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex. Proteins: Struct. Funct. Genet. 29 (1997) 186-192
27. Mylari B.L., Larson E.R., Beyer T.A., Zembrowski W.J., Aldinger C.E., and Dee M.F. Novel, potent aldose reductase inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazine-acetic acid (Zopolrestat) and congeners. J. Med. Chem. 34 (1991) 108-122
28. Kotani T., Nagaki Y., Ishii A., Konishi Y., Yago H., Suehiro S., et al. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(Arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. J. Med. Chem. 40 (1997) 684-694
29. Mizuno K., Yamaguchi T., Unoue A., Tomiya N., Unno R., Miura K., et al. Profile of a new aldose reductase inhibitor (2S,4S)-6-fluoro-2′.5′-dioxyspiro [chroman-4,4′-imidazoline]-2-carboxamide. Excerpta Med. 913 (1990) 89-96
30. Petrash J.M., Harter T.M., Devine C.S., Olins P.O., Bhatnagar A., Liu S., and Srivastava S.K. Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. J. Biol. Chem. 267 (1992) 24833-24840
31. Grimshaw C.E., Bohren K.M., Lai C.-J., and Gabbay K.H. Human aldose reductase: Subtle effects revealed by rapid kinetic studies of the C298A mutant enzyme. Biochemistry 34 (1995) 14366-14373
32. Homans S.W. Probing the binding entropy of ligand protein interactions by NMR. ChemBioChem 6 (2005) 1-8
33. El-Kabbani O., Darmanin C., Schneider T.R., Hazemann I., Ruiz F., Oka M., et al. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. Proteins: Struct. Funct. Genet. 55 (2004) 805-813
34. Howard E.I., Sanishvili R., Cachau R.E., Mitschler A., Chevrier B., Barth P., et al. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Proteins: Struct. Funct. Genet. 55 (2004) 792-804
35. Van Zandt M.C., Sibley E.O., McCann E.E., Combs K.J., Flam B., Sawicki D.R., et al. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications. Bioorg. Med. Chem. 12 (2004) 5661-5675
36. Steuber H., Zentgraf M., Gerlach C., Sotriffer C.A., Heine A., and Klebe G. Expect the unexpected or caveat for drug designers: Multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallization conditions. J. Mol. Biol. 363 (2006) 174-187
37. Steuber H., Heine A., and Klebe G. Structural and thermodynamic characterization of Aldose Reductase inhibitors reveals a nitro substituent as strong enthalpic contributor to ligand affinity. J. Mol. Biol. 368 (2007) 618-638
38. Petrova T., Steuber H., Hazemann I., Cousido-Siah A., Mitschler A., Chung R., et al. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: Structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex. J. Med. Chem. 48 (2005) 5659-5665
39. Meyer E.A., Castellano R.K., and Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew. Chem. Int. Ed. 42 (2003) 1210-1250
40. Ruben A.J., Kiso Y., and Freire E. Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem. Biol. Drug Des. 67 (2006) 2-4
41. Steuber H., Czodrowski P., Sotriffer C.A., and Klebe G. Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase. J. Mol. Biol. 373 (2007) 1305-1320
42. Dullweber F., Stubbs M.T., Musil D., Stürzebecher J., and Klebe G. Factorizing ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J. Mol. Biol. 313 (2001) 593-614
43. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
44. Calderone V., Chevrier B., Van Zandt M., Lamour V., Howard E., Poterszman A., et al. The structure of human aldose reductase bound to the inhibitor IDD 384. Acta Crystallogr. D 56 (2000) 536-540
45. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54 (1998) 905-921
46. Sheldrick G.M., and Schneider T. SHELXL: high-resolution refinement. Methods Enzymol. 277 (1997) 319-343
47. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
48. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60 (2004) 2126-2132
49. Laskowski R., MacArthur M., Moss D., and Thornton J. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291